Literature DB >> 20947262

The expression of MUC mucin in cholangiocarcinoma.

Anwar S Mall1, Marilyn G Tyler, Sam B Ho, Jake E J Krige, Delawir Kahn, Wendy Spearman, Landon Myer, Dhirendra Govender.   

Abstract

Cholangiocarcinoma (CC) is a highly malignant epithelial cancer of the biliary tract, the cellular and molecular pathogenesis of which remains unclear. Malignant transformation of glandular epithelial cells is associated with the altered expression of mucin. We investigated the type of mucins expressed in CC. Twenty-six patients with histologically confirmed CC were included in this study. The expression of mucin was studied by immunohistochemistry using antibodies to MUC1, MUC1 core, MUC2, MUC3, MUC4, MUC5AC, and MUC6. There was extensive (>50%) expression of mucin, mainly MUC1 in 11/25 and MUC5AC in 12/26 cases. In the case of MUC3, 6/26 cases expressed mucin extensively, whilst only 1/26 had MUC2, MUC4, and MUC6 expression. Well-differentiated tumors significantly expressed MUC3 extensively compared to poor or moderately differentiated tumors (p=0.003). Fifteen of 25 cases had metastatic disease. MUC1 was extensively expressed in 9/15 cases with metastatic disease. In contrast, MUC1 expression was present in 2/10 cases where metastases were absent. Hilar lesions were less likely to express MUC1, but this was not statistically significant. Fifteen of 25 cases had metastatic disease. Extensive MUC3 expression was significantly associated with well-differentiated tumors, whilst there was an approaching significance between the extensive expression of MUC1 and metastasis in cholangiocarcinoma.
Copyright © 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20947262     DOI: 10.1016/j.prp.2010.08.004

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  15 in total

Review 1.  Immunotherapeutic Approaches to Biliary Cancer.

Authors:  Urvi A Shah; Amara G Nandikolla; Lakshmi Rajdev
Journal:  Curr Treat Options Oncol       Date:  2017-07

Review 2.  Optimum chemotherapy for the management of advanced biliary tract cancer.

Authors:  Marwan Ghosn; Hampig Raphael Kourie; Elie El Rassy; Ralph Chebib; Fadi El Karak; Colette Hanna; Dolly Nasr
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

Review 3.  Immunotherapy of biliary tract cancer.

Authors:  Yi Chai
Journal:  Tumour Biol       Date:  2016-01-04

Review 4.  Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer.

Authors:  Lukas Perkhofer; Alica K Beutel; Thomas J Ettrich
Journal:  Visc Med       Date:  2019-02-07

5.  Potential prognostic biomarkers of pancreatic cancer.

Authors:  Kathryn T Chen; Phillip D Kim; Kelly A Jones; Karthik Devarajan; Bhavinkumar B Patel; John P Hoffman; Hormoz Ehya; Min Huang; James C Watson; Jeffrey L Tokar; Anthony T Yeung
Journal:  Pancreas       Date:  2014-01       Impact factor: 3.327

Review 6.  Current status of immunotherapy for the treatment of biliary tract cancer.

Authors:  Ryuji Takahashi; Munehiro Yoshitomi; Shigeru Yutani; Takahisa Shirahama; Masanori Noguchi; Akira Yamada; Kyogo Itoh; Tetsuro Sasada
Journal:  Hum Vaccin Immunother       Date:  2013-02-01       Impact factor: 3.452

7.  EVI1 expression is associated with aggressive behavior in intrahepatic cholangiocarcinoma.

Authors:  Mariko Tanaka; Junji Shibahara; Shumpei Ishikawa; Tetsuo Ushiku; Teppei Morikawa; Aya Shinozaki-Ushiku; Akimasa Hayashi; Kento Misumi; Atsushi Tanaka; Hiroto Katoh; Kei Sakuma; Takashi Kokudo; Yoshinori Inagaki; Junichi Arita; Yoshihiro Sakamoto; Kiyoshi Hasegawa; Masashi Fukayama
Journal:  Virchows Arch       Date:  2018-10-23       Impact factor: 4.064

Review 8.  The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma.

Authors:  Oraianthi Fiste; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Michalis Liontos; Konstantinos Koutsoukos; Meletios Athanasios Dimopoulos; Flora Zagouri
Journal:  Vaccines (Basel)       Date:  2021-04-22

9.  A comprehensive expression analysis of mucins in appendiceal carcinoma in a multicenter study: MUC3 is a novel prognostic factor.

Authors:  Hiroaki Shibahara; Michiyo Higashi; Seiya Yokoyama; Karine Rousseau; Iwao Kitazono; Masahiko Osako; Hiroshi Shirahama; Yukie Tashiro; Yasuhiro Kurumiya; Michihiko Narita; Shingo Kuze; Hiroshi Hasagawa; Takehito Kato; Hitoshi Kubota; Hideaki Suzuki; Toshiyuki Arai; Yu Sakai; Norihiro Yuasa; Masahiko Fujino; Shinji Kondo; Yoshichika Okamoto; Tatsuyoshi Yamamoto; Takashi Hiromatsu; Eiji Sasaki; Kazuhisa Shirai; Satoru Kawai; Koutarou Hattori; Hideki Tsuji; Osamu Okochi; Masaki Sakamoto; Akinobu Kondo; Naomi Konishi; Surinder K Batra; Suguru Yonezawa
Journal:  PLoS One       Date:  2014-12-31       Impact factor: 3.240

10.  The silence of MUC2 mRNA induced by promoter hypermethylation associated with HBV in Hepatocellular Carcinoma.

Authors:  Yang Ling; Jing Zhu; Lu Gao; Yongping Liu; Changtai Zhu; Rong Li; Lixin Wei; Changsong Zhang
Journal:  BMC Med Genet       Date:  2013-01-25       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.